348 related articles for article (PubMed ID: 28458054)
1. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
Guo W; Wang SJ; Yang S; Lynn H; Ji Y
Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
[TBL] [Abstract][Full Text] [Related]
2. A modified toxicity probability interval method for dose-finding trials.
Ji Y; Liu P; Li Y; Bekele BN
Clin Trials; 2010 Dec; 7(6):653-63. PubMed ID: 20935021
[TBL] [Abstract][Full Text] [Related]
3. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
Horton BJ; Wages NA; Conaway MR
Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
[TBL] [Abstract][Full Text] [Related]
4. Comparative review of novel model-assisted designs for phase I clinical trials.
Zhou H; Murray TA; Pan H; Yuan Y
Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
[TBL] [Abstract][Full Text] [Related]
5. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
6. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.
Yan F; Mandrekar SJ; Yuan Y
Clin Cancer Res; 2017 Aug; 23(15):3994-4003. PubMed ID: 28546227
[TBL] [Abstract][Full Text] [Related]
7. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR
Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096
[TBL] [Abstract][Full Text] [Related]
8. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
Ji Y; Wang SJ
J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
[TBL] [Abstract][Full Text] [Related]
9. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.
Hirakawa A; Hamada C; Matsui S
Stat Med; 2013 Nov; 32(26):4515-25. PubMed ID: 23650098
[TBL] [Abstract][Full Text] [Related]
10. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
Zhou H; Yuan Y; Nie L
Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
[TBL] [Abstract][Full Text] [Related]
11. R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials.
Guo W; Ji Y; Li D
J Biopharm Stat; 2019; 29(3):411-424. PubMed ID: 30744484
[TBL] [Abstract][Full Text] [Related]
12. Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology.
Lin X; Ji Y
Stat Methods Med Res; 2021 Mar; 30(3):843-856. PubMed ID: 33327870
[TBL] [Abstract][Full Text] [Related]
13. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial design for drug combinations with Bayesian model averaging.
Jin IH; Huo L; Yin G; Yuan Y
Pharm Stat; 2015; 14(2):108-19. PubMed ID: 25641851
[TBL] [Abstract][Full Text] [Related]
15. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
16. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
Lin R; Yin G
Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
[TBL] [Abstract][Full Text] [Related]
17. A novel Bayesian seamless phase I/II design.
Pan H; Huang P; Wang Z; Wang L; Li C; Xia J
PLoS One; 2013; 8(9):e73060. PubMed ID: 24023809
[TBL] [Abstract][Full Text] [Related]
18. On the relative efficiency of model-assisted designs: a conditional approach.
Lin R; Yuan Y
J Biopharm Stat; 2019; 29(4):648-662. PubMed ID: 31258039
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian dose finding design for dual endpoint phase I trials.
Loke YC; Tan SB; Cai Y; Machin D
Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
[TBL] [Abstract][Full Text] [Related]
20. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
